A combination therapy that targets cancer cells from within and without caused tumours to shrink or stabilise in 75% of patients with recurrent or persistent oestrogen receptor- (ER-) positive endometrial cancer, results from a recent clinical trial show. Trial leaders from Dana-Farber Cancer Institute will present the findings at today’s session of the Society of Gynecologic Oncology (SGO) Annual Meeting.
The phase 2 study evaluated the combination of abemaciclib, a targeted drug, and letrozole, an aromatase inhibitor, in 30 patients with recurrent ER-positive endometrial cancer, a form of the disease in which tumour growth is fueled by oestrogen. The patients had received a median of three prior therapies, and about half of them had been treated with hormonal therapy.
With a median follow-up of 12.5 months, 75% of the patients had their tumours shrink or become stable. About 30% of the participants had their tumours shrink by more than 30%. The benefits were persistent: the median time before the disease began to worsen was 9.1 months.
The two-drug regimen was tolerable for most patients: only two left the study because of toxic side effects. Some patients continued to benefit from the treatment and remained on the trial for more than a year. Two have been on it for more than two years.
“When we compare the efficacy of this regimen with that of other endocrine therapies for endometrial cancer, we can see this combination is extremely promising,” says Dana-Farber’s Panagiotis Konstantinopoulos, MD, PhD, the first author of the study, who will present the findings at SGO. “Our findings suggest it will be a very effective alternate endocrine therapy for patients with recurrent endometrial cancer whose tumours express the oestrogen receptor.”
Endometrial cancer, which begins in the lining of the uterus, is the sixth most common cancer worldwide, diagnosed in more than 400,000 women every year. The majority of endometrial tumours are ER-positive.
Endocrine therapy, which seeks to reduce the amount of oestrogen reaching tumour cells, is an option for patients whose cancer has begun to grow after chemotherapy and immunotherapy, or for those whose cancer is slow-growing and produces relatively mild symptoms. Because the benefits of such therapy tend to be fairly modest and short-lived, researchers are exploring ways to improve its efficacy.
Letrozole works by preventing an enzyme in fat tissue from converting certain hormones into oestrogen, thereby lowering overall oestrogen levels. Abemaciclib blocks the CDK4 and CDK6 proteins, which play a key role in cell proliferation.
Combining these agents provides a two-pronged attack on ER-positive endometrial cancer cells, taking out a key cog in their growth machinery while lowering the availability of oestrogen.
Analysis of patients’ tumour tissue showed that responses to the regimen occurred regardless of a tumour’s grade (how abnormal its cells look under a microscope), prior treatment with hormonal therapy, or the presence or absence of progesterone receptors on tumour cells.
All patients whose tumour cells harboured mutations in the KRAS, CTNNB1 or CDK2NA genes responded to the therapy, while those whose tumours had TP53 mutations were less likely to respond.
“Based on our findings, the letrozole/abemaciclib combination should be considered worthy of further evaluation for patients with recurrent ER-positive endometrial cancer,” Konstantinopoulos said.
Source: Dana-Farber Cancer Institute
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.